PMV Pharmaceuticals (Nasdaq:PMVP) - Aandelenkoers, Nieuws & Analyse

PMVP Overzicht aandelen

PMVP fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Analisten zijn het erover eens dat de aandelenkoers met 264.8% zal stijgen

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

De winst zal naar verwachting de komende drie jaar met gemiddeld 0.7% per jaar dalen.

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Heeft geen betekenisvolle marktkapitalisatie ( $82M )

PMV Pharmaceuticals, Inc. Concurrenten

FibroBiologics

NasdaqGM:FBLG

US$90.1m

Invivyd

NasdaqGM:IVVD

US$83.9m

Genelux

NasdaqCM:GNLX

US$87.3m

Chimerix

NasdaqGM:CMRX

US$80.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor PMV Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$1.59
52 Week Hoogtepunt	US$3.47
52 Week Laag	US$1.40
Bèta	1.48
11 maand verandering	-4.22%
3 maanden verandering	0%
1 Jaar Verandering	-28.70%
33 jaar verandering	-92.69%
5 jaar verandering	n/a
Verandering sinds IPO	-95.76%

Recent nieuws en updates

Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?

Aug 04

Recent updates

Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?

Aug 04

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Apr 20

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Dec 22

We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth

Sep 08

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

May 10

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

Jan 11

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Sep 22

PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04

Aug 09

PMV Pharma joins Merck to study lead candidate with Keytruda

Jul 18

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Jun 09

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Feb 23

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Nov 05

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Jul 23

Rendement voor aandeelhouders

	PMVP	US Biotechs	US Markt
7D	0%	4.0%	2.2%
1Y	-28.7%	18.3%	32.6%

Rendement versus industrie: PMVP presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 18.3 % opleverde.

Rendement versus markt: PMVP presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 32.6 % opleverde.

Prijsvolatiliteit

Is PMVP's price volatile compared to industry and market?
PMVP volatility
PMVP Average Weekly Movement	5.4%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: PMVP heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van PMVP is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2013	63	David Mack	www.pmvpharma.com

PMV Pharmaceuticals, Inc., een precisie oncologie bedrijf, houdt zich bezig met het ontdekken en ontwikkelen van kleine molecule en tumoragnostische therapieën voor p53 mutaties in kanker. De belangrijkste productkandidaat is PC14586, een kleine molecule die gemuteerd p53-eiwit met de Y220C-mutatie corrigeert en de wild-type p53-functie herstelt. Het bedrijf was voorheen bekend als PJ Pharmaceuticals, Inc. en veranderde zijn naam in PMV Pharmaceuticals, Inc. in juli 2013.

PMV Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van PMV Pharmaceuticals zich tot de beurswaarde?
PMVP fundamentele statistieken
Marktkapitalisatie	US$82.28m
Inkomsten(TTM)	-US$51.46m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-1.6x

Koers/Winstverhouding

Is PMVP overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
PMVP resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$51.47m
Inkomsten	-US$51.46m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.99
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde PMVP op de lange termijn?

Bekijk historische prestaties en vergelijking

PMVP Overzicht aandelen

Beloningen

Risicoanalyse

PMV Pharmaceuticals, Inc. Concurrenten

NasdaqGM:FBLG

US$90.1m

NasdaqGM:IVVD

US$83.9m

NasdaqCM:GNLX

US$87.3m

NasdaqGM:CMRX

US$80.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New major risk - Revenue and earnings growth

PMV Pharmaceuticals, Inc. Provides A Progress Update on PYNNACLE Clinical Trial

Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?

PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 3000 Index

Insufficient new directors

PMV Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Recent updates

New major risk - Revenue and earnings growth

PMV Pharmaceuticals, Inc. Provides A Progress Update on PYNNACLE Clinical Trial

Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?

PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 3000 Index

Insufficient new directors

PMV Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Price target decreased by 54% to US$5.67

PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer

PMV Pharmaceuticals, Inc. Announces Workforce Reduction of Approximately 30%

New minor risk - Market cap size

PMV Pharmaceuticals, Inc. Announces Chief Financial Officer Changes

PMV Pharmaceuticals, Inc. Announces Chief Financial Officer Changes

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Price target decreased by 39% to US$13.20

New minor risk - Market cap size

PMV Pharmaceuticals, Inc. Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types with TP53 Y220C Mutation

New major risk - Share price stability

PMV Pharmaceuticals, Inc. to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth

New minor risk - Share price stability

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$38.50

PMV Pharmaceuticals, Inc. Announces Board Changes

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04

PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

PMV Pharma joins Merck to study lead candidate with Keytruda

PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 2000 Growth Index

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

PMV Pharmaceuticals, Inc. Announces Preliminary Results from the Ongoing Phase 1/2 PYNNACLE Study of PC14586 in Patients

Price target decreased to US$43.33

PMV Pharmaceuticals, Inc. to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Price target decreased to US$49.00

PMV Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2022

Price target decreased to US$53.17

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Chief Medical Officer exercised options and sold US$103k worth of stock

Co-Founder notifies of intention to sell stock

Insider exercised options and sold US$88k worth of stock

COO & CFO exercised options and sold US$138k worth of stock

Co-Founder notifies of intention to sell stock

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

COO & CFO exercised options and sold US$137k worth of stock

PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 2500 Value Index

Co-Founder notifies of intention to sell stock

Key Executive exercised options and sold US$832k worth of stock

Co-Founder notifies of intention to sell stock

COO & CFO exercised options and sold US$137k worth of stock

Chief Medical Officer exercised options and sold US$120k worth of stock

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business

PMV Pharmaceuticals, Inc. Appoints Guillermina Lozano to Scientific Advisory Board

New 90-day high: US$61.51

Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?

PMV Pharmaceuticals, Inc. Doses First Patient in Phase 1/2 Study of PC14586, a First-In-Class Precision Oncology Therapy That Targets Mutant P53

PMV Pharmaceuticals reports Q3 results